{"id":11602,"date":"2003-09-01T05:39:05","date_gmt":"2003-09-01T05:39:05","guid":{"rendered":"http:\/\/i-base.info\/htb\/?p=11602"},"modified":"2014-05-27T11:46:23","modified_gmt":"2014-05-27T11:46:23","slug":"first-results-from-esprit-study-cd4-response-to-il-2-is-associated-with-higher-nadir-and-baseline-cd4-and-younger-age","status":"publish","type":"post","link":"https:\/\/i-base.info\/htb\/11602","title":{"rendered":"First results from ESPRIT study: CD4 response to IL-2 is associated with higher nadir and baseline CD4 and younger age"},"content":{"rendered":"<p><strong>Graham McKerrow, HIV i-Base<\/strong><\/p>\n<p><strong>Preliminary results of the multinational ESPRIT (Evaluation of Subcutaneous Proleukin in a Randomised International Trial) showed that CD4 cell count response after the first three cycles of IL-2, used in addition to HAART in patients with baseline CD4 counts &gt;300 cells\/ml, at month eight, is associated with higher nadir CD4 count, higher baseline CD4 and younger age.<\/strong><\/p>\n<p>Of the 1,142 patients who completed three cycles of IL-2 by month eight, 9% were classified as \u2018non-responders\u2019 because they had CD4 counts below their baseline values. There were 4.6% who had a small increase of less than 50 cells\/mm3, and 22.4% who had an increase of between 51 and 200 cells\/mm3. The remaining participants, almost 70%, were classified as \u2018responders\u2019 because they had an increase of at least 200 cells\/mm3 but 27% did not reach the predefined primary endpoint goal, defined as a doubling of the baseline CD4 count or reaching 1,000 cells\/mm3 (whichever is lower) and 36% did.<\/p>\n<p>The following factors were associated with CD4 response (&gt;200 cell\/mm3 increase or above CD4 goal at eight months): higher nadir CD4 (P&lt;0.001), higher baseline CD4 (P=0.02), and younger age (P=0.03). Odds of response increased by 28% and 11% respectively, for a higher nadir and baseline CD4 count of 100 cells\/mm3, and by 19% for 10-year younger age. There was no evidence of an association with viral load &lt;500 copies\/ml, hepatitis C or B status, time on antiretroviral therapy, prior progression of disease or gender<\/p>\n<p>Ref: Weiss L, Aboulhab J, Babiker GA et al. Preliminary results of ESPRIT (Evaluation of Subcutaneous Proleukin in a Randomised International Trial): baseline predictors of CD4 T-cell response to Interleukin-2. \u00a02nd IAS Conference on HIV Pathogenesis and Treatment, 13-16 July 2003, Paris.\u00a0Abstract 13.<\/p>\n<h3>Comment<\/h3>\n<p><strong>Results from this large international study, which has recruited almost 4,000 patients and will follow them for five years, provides evidence that IL-2 can significantly boost CD4 levels in a majority of patients.<\/strong><\/p>\n<p><strong>It is a concern that almost 10% of patients saw their CD4 count drop and 5% had an increase of less than 50 cells\/mm3 given that these patients are also on background HAART regimens, and also given the significant side effects associated with the weeks when IL-2 is taken.<\/strong><\/p>\n<p><strong>Data were not presented from the control arm of the study randomised to continue HAART without IL-2.<\/strong><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Graham McKerrow, HIV i-Base Preliminary results of the multinational ESPRIT (Evaluation of Subcutaneous Proleukin in a Randomised International Trial) showed that CD4 cell count response after the first three cycles of IL-2, used in addition to HAART in patients with &hellip;<\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[4,15],"tags":[],"class_list":["post-11602","post","type-post","status-publish","format-standard","hentry","category-conference-reports","category-basic-science-and-immunology"],"_links":{"self":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/11602","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/comments?post=11602"}],"version-history":[{"count":0,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/11602\/revisions"}],"wp:attachment":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/media?parent=11602"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/categories?post=11602"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/tags?post=11602"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}